Classified in: Health
, Science and technologySubjects: Conference
, Trade Show
Final Day of BIO International Convention Begins in Philadelphia
BIO International Convention, the
world's premier life sciences event, kicked off its fourth and final day
of programming today under the theme "It Starts With One." This year's
theme recognizes many of the "ones"? one partnership, one idea, one
question, one "a-ha" moment ? that can lead to globally important
advancements in biotech.
The final day of Convention programming will include a Super Session
with Nature Biotechnology and Scientific American WORLDVIEW
on the main drivers of biotech innovation in markets around the world.
The day's agenda will also include Start-up Stadium presentations and
educational sessions on topics such as personalized medicine in cancer
care, clinical trial design for rare disease, and the evolving landscape
of biotech venture capital, among other topics.
Thursday, June 6, Highlights Include:
Super Session: Nature
Biotechnology and Scientific American WORLDVIEW: Biotech Innovation in
a Faster Future
12:00?1:30 pm | 113ABC, Level 100
session will tackle the latest commercial, scientific and ethical
issues facing innovation stakeholders today. Panel members will share
their views of on the future of biotech innovation.
10:30 am?1:00 pm | Exhibitor Hall, 3971, Level
Designed to provide start-up-level companies with the
opportunity to engage key members of the investment community and
venture philanthropy groups. BIO attendees can watch these impressive
companies pitch their products to a panel of investor judges.
and Economic Value of Personalized Cancer Treatment
AM?10:15 AM | 116, Level 100
This session will
feature a discussion on the clinical utility and economic value of
NGS-based diagnostic testing in cancer care. Panelists will highlight
data sources and original research results that will provide clinical
utility and health economic value evidence of genomic profiling
Finds: Innovative Clinical Trial Design for Rare and Orphan Diseases
AM?11:45 AM | 106AB, Level 100
Attendees will hear from
biotech companies who are addressing the challenges of rare disease
trial design head-on, through innovative strategies for identifying
potential enrollees, data gathering and even identifying new
biomarkers to serve as clinical endpoints.
Evolving Landscape of Venture Capital
AM | 107AB, Level 100
This session will bring together
traditional and corporate venture capitalists to share perspectives on
the factors fueling further investment in human healthcare. Panelists
will also share views of the current entrepreneurial scene and how it
will change in 2019.
Follow the 2019 Convention @BIOConvention
and join the conversation @IAmBIOtech.
BIO is the world's largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention, the world's largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW is
BIO's blog chronicling "innovations transforming our world" and the BIO
Newsletter is the organization's bi-weekly email newsletter. Subscribe
to the BIO Newsletter.
These press releases may also interest you
News published on 6 june 2019 at 07:05 and distributed by: